热休克蛋白和热休克因子1在多发性骨髓瘤发病机制及治疗中的研究现状  

Current status of heat shock proteins and heat shock factor 1 in pathogenesis and treatment of multiple myeloma

作　　者：左李平 孙春艳[1] Zuo Liping;Sun Chunyan(Institute of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China)

机构地区：[1]华中科技大学同济医学院附属协和医院血液科,武汉430022

出　　处：《国际输血及血液学杂志》2021年第4期294-301,共8页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金(81670197、81974007)。

摘　　要：热休克蛋白(HSP)作为"分子伴侣"在蛋白质折叠、装配、转运和降解等方面,均发挥着重要作用。研究发现,肿瘤细胞的HSP水平高于正常细胞,HSP过表达在肿瘤发生、发展过程中,发挥着重要作用,并且影响肿瘤患者预后。热休克因子(HSF)1是调控真核生物热休克反应(HSR),并诱导HSP表达的主要转录因子,同时也是肿瘤发生的重要调节因子之一。近年越来越多的研究证据表明,HSP/HSF1与多发性骨髓瘤(MM)的发生及发展密切相关,HSP/HSF1作为MM的潜在治疗靶点,已受到相关研究者的重视。笔者就HSP/HSF1在MM发生及发展中的作用,HSP/HSF1抑制剂治疗MM的研究现状进行阐述,旨在为探索MM治疗的新靶点,以及改善患者预后提供参考。As molecular chaperones,heat shock proteins(HSP)play an important role in protein folding,assembly,transport and degradation.Studies have found that HSP level in tumor cells is higher than that in normal cells,and over-expressed HSP play an important role in development and affect therapeutic effect of tumor.Heat shock factor(HSF)1 is a major transcription factor regulating eukaryotic heat shock response(HSR)and inducing expression of HSP,and it is also an important regulator of tumorigenesis.In recent years,more and more evidences show that HSP/HSF1 closely related to occurrence and development of multiple myeloma(MM),and HSP/HSF1 as potential therapeutic targets of MM have been valued by researchers.This article summarizes latest research status of HSP/HSF1 in occurrence and development of MM,and HSP/HSF1 inhibitors in treatment of MM,aiming to provide a reference for exploring new targets for treatment of MM and improve prognosis of patients with MM.

关 键 词：热休克蛋白质类 热休克反应 多发性骨髓瘤 药物疗法 热休克因子1 发病机制 

分 类 号：R733.3[医药卫生—肿瘤]